Mark H. Drazner

51.7k total citations · 10 hit papers
236 papers, 18.9k citations indexed

About

Mark H. Drazner is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Biomedical Engineering. According to data from OpenAlex, Mark H. Drazner has authored 236 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Cardiology and Cardiovascular Medicine, 73 papers in Surgery and 30 papers in Biomedical Engineering. Recurrent topics in Mark H. Drazner's work include Cardiovascular Function and Risk Factors (87 papers), Heart Failure Treatment and Management (84 papers) and Cardiac Structural Anomalies and Repair (30 papers). Mark H. Drazner is often cited by papers focused on Cardiovascular Function and Risk Factors (87 papers), Heart Failure Treatment and Management (84 papers) and Cardiac Structural Anomalies and Repair (30 papers). Mark H. Drazner collaborates with scholars based in United States, Canada and Brazil. Mark H. Drazner's co-authors include James A. de Lemos, Lynne W. Stevenson, Biykem Bozkurt, Clyde W. Yancy, Darren K. McGuire, Gregg C. Fonarow, Steven M. Hollenberg, Pamela N. Peterson, Michael M. Givertz and Mariell Jessup and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark H. Drazner

218 papers receiving 18.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

2017 2.8k citations Clyde W. Yancy, Mark H. Drazner et al. profile →
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

2017 2.1k citations Clyde W. Yancy, Mark H. Drazner et al. Circulation profile →
B-type natriuretic peptide in cardiovascular disease

2003 845 citations James A. de Lemos, Mark H. Drazner et al. profile →
Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population

2010 842 citations James A. de Lemos, Mark H. Drazner et al. profile →
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

2016 696 citations Clyde W. Yancy, Javed Butler et al. Circulation profile →
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

2017 575 citations Clyde W. Yancy, Mark H. Drazner et al. Journal of Cardiac Failure profile →
The Progression of Hypertensive Heart Disease

2011 564 citations Mark H. Drazner Circulation profile →
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

2016 454 citations Clyde W. Yancy, Mark H. Drazner et al. profile →
Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction

2014 357 citations Ambarish Pandey, Benjamin D. Levine et al. Circulation Heart Failure profile →
2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis

2024 33 citations Mark H. Drazner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark H. Drazner United States	57	14.4k	3.3k	2.3k	1.8k	1.7k	236	18.9k
Frank Ruschitzka Switzerland	61	14.8k 1.0×	3.8k 1.2×	2.7k 1.2×	2.2k 1.2×	1.9k 1.1×	384	21.4k
Inder S. Anand United States	81	17.6k 1.2×	2.9k 0.9×	3.0k 1.3×	1.6k 0.9×	1.6k 1.0×	420	23.2k
Richard J. Rodeheffer United States	68	18.1k 1.3×	3.7k 1.1×	3.0k 1.3×	3.2k 1.8×	2.2k 1.3×	198	23.8k
Alan S. Maisel United States	74	16.6k 1.2×	3.4k 1.0×	3.4k 1.5×	1.6k 0.9×	2.0k 1.2×	423	23.2k
Charalambos Vlachopoulos Greece	56	12.7k 0.9×	2.7k 0.8×	3.3k 1.5×	1.5k 0.8×	941 0.6×	308	18.3k
G. Michael Felker United States	83	17.3k 1.2×	4.3k 1.3×	4.2k 1.8×	1.3k 0.7×	2.5k 1.5×	417	24.0k
Ian B. Wilkinson United Kingdom	78	18.3k 1.3×	3.6k 1.1×	5.0k 2.2×	1.8k 1.0×	1.3k 0.8×	346	25.2k
Javed Butler United States	59	11.4k 0.8×	2.1k 0.6×	2.4k 1.1×	995 0.6×	2.2k 1.3×	406	16.0k
Mihai Gheorghiade United States	63	13.5k 0.9×	2.1k 0.6×	3.5k 1.5×	1.1k 0.6×	1.3k 0.8×	205	16.7k
Torbjørn Omland Norway	57	13.6k 0.9×	3.0k 0.9×	3.1k 1.4×	2.5k 1.4×	1.8k 1.1×	332	18.6k

Countries citing papers authored by Mark H. Drazner

Since Specialization

Citations

This map shows the geographic impact of Mark H. Drazner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H. Drazner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H. Drazner more than expected).

Fields of papers citing papers by Mark H. Drazner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark H. Drazner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H. Drazner. The network helps show where Mark H. Drazner may publish in the future.

Co-authorship network of co-authors of Mark H. Drazner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark H. Drazner. A scholar is included among the top collaborators of Mark H. Drazner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark H. Drazner. Mark H. Drazner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manla, Yosef, Amanda R. Vest, Lisa Anderson, et al.. (2025). Global Innovations in the Care of Patients With Heart Failure. PubMed. 7(2). 47–47.

Grodin, Justin L., Anand Gupta, Julia Kozlitina, et al.. (2025). Risk for Heart Failure and Atrial Fibrillation Across the Lifespan for Carriers of the Amyloidogenic p.V142I TTR Variant. Circulation Genomic and Precision Medicine. 18(4). e004911–e004911. 1 indexed citations

Gómez‐Mesa, Juan Esteban, et al.. (2024). American Registry of Ambulatory and Acute Decompensated Heart Failure (AMERICCAASS Registry): Rationale and Design. ESC Heart Failure. 11(6). 3805–3813. 2 indexed citations

Thibodeau, Jennifer T., et al.. (2024). Kussmaul’s Sign by Point-of-Care Ultrasound. Circulation Heart Failure. 17(6). e011714–e011714.

Thomas, Melanie B., Maryjane Farr, L. Truby, et al.. (2024). Glucagon-like peptide-1 agonist use for obesity treatment in patients with left ventricular assist devices. SHILAP Revista de lepidopterología. 5. 100114–100114.

Edwards, M. J., Melanie B. Thomas, L. Truby, et al.. (2024). Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices. The Journal of Heart and Lung Transplantation. 43(4). S23–S23.

Thibodeau, Jennifer T., Nicholas Hendren, & Mark H. Drazner. (2023). Voluntary Reporting of Guideline-Directed Medical Therapy Use Rates in the Public Domain: A Challenge to the Heart Failure Community. Journal of Cardiac Failure. 29(5). 858–860.

Segar, Matthew W., Muhammad Shahzeb Khan, Kershaw V. Patel, et al.. (2023). A Phenomapping Tool and Clinical Score to Identify Low Diuretic Efficiency in Acute Decompensated Heart Failure. JACC Heart Failure. 12(3). 508–520. 13 indexed citations

Thibodeau, Jennifer T., et al.. (2021). Subclinical Myocardial Injury and the Phenotype of Clinical Congestion in Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. Journal of Cardiac Failure. 28(3). 422–430. 3 indexed citations

10.

Michelis, Katherine C., Justin L. Grodin, Lin Zhong, et al.. (2021). Discordance Between Severity of Heart Failure as Determined by Patient Report Versus Cardiopulmonary Exercise Testing. Journal of the American Heart Association. 10(13). e019864–e019864. 3 indexed citations

11.

Hendren, Nicholas, Matthew W. Segar, Lin Zhong, et al.. (2021). Phenomapping a Novel Classification System for Patients With Destination Therapy Left Ventricular Assist Devices. The American Journal of Cardiology. 164. 93–99. 2 indexed citations

12.

Drazner, Mark H., Colby Ayers, Justin L. Grodin, et al.. (2021). Identifying Discordance of Right- and Left-Ventricular Filling Pressures in Patients With Heart Failure by the Clinical Examination. Circulation Heart Failure. 14(11). e008779–e008779. 9 indexed citations

13.

Lewis, Alana, Colby Ayers, Elizabeth Selvin, et al.. (2020). Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure. Circulation. 141(12). 957–967. 34 indexed citations

14.

Hendren, Nicholas, James A. de Lemos, Colby Ayers, et al.. (2020). Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19. Circulation. 143(2). 135–144. 183 indexed citations

15.

Michelis, Katherine C., Lin Zhong, Matthias Peltz, et al.. (2020). Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS. Journal of the American Heart Association. 9(14). e016203–e016203. 3 indexed citations

16.

Gore, M. Odette, Colby Ayers, Amit Khera, et al.. (2020). Combining Biomarkers and Imaging for Short‐Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. Journal of the American Heart Association. 9(15). e015410–e015410. 19 indexed citations

17.

Hendren, Nicholas, Mark H. Drazner, Ambarish Pandey, W.H. Wilson Tang, & Justin L. Grodin. (2019). Implications of Perceived Dyspnea and Global Well-Being Measured by Visual Assessment Scales During Treatment for Acute Decompensated Heart Failure. The American Journal of Cardiology. 124(3). 402–408. 3 indexed citations

18.

Darden, Douglas, Mark H. Drazner, Wilfried Müllens, et al.. (2019). Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. Clinical Cardiology. 42(10). 1010–1018. 4 indexed citations

19.

Fudim, Marat, Kishan S. Parikh, Allison Dunning, et al.. (2018). Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). The American Journal of Cardiology. 122(9). 1506–1512. 12 indexed citations

20.

Kitchell, Ellen, et al.. (2012). Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient. SHILAP Revista de lepidopterología. 2012. 1–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact